Treatment costs associated with commonly used branded antibiotics for the management of acute sinusitis, chronic bronchitis and pneumonia

Journal of Applied Research

Volumn 4, Issue 1, 2004, Pages 24-36

  Barron, John J ^a   Grochulski, W Daniel ^a   Merchant, Sanjay ^b   Spooner, Joshua J ^a   Waugh, William J ^c   Keating, Karen N ^b  

^a HEALTHCORE INC   (United States)

^b BAYER CORPORATION   (United States)

^c Wellpoint Inc   (United States)

Author keywords

Acute sinusitis; Antibiotic; Chronic bronchitis; Community acquired pneumonia; Cost

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ADULT; ARTICLE; CHRONIC BRONCHITIS; COMMUNICABLE DISEASE; CONFIDENCE INTERVAL; CONSULTATION; COST OF ILLNESS; DRUG COST; EMERGENCY WARD; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; OUTPATIENT CARE; PNEUMONIA; PRESCRIPTION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SINUSITIS; TREATMENT FAILURE; UNITED STATES;

EID: 6444231833     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269-1276.
2. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278:901-904.
3. Merchant S, Mullins CD, Shih YC. Factors associated with hospitalization costs for patients with community-acquired pneumonia. Clin Ther. 2003;25:593-610.
4. Centers for Disease Control and Prevention. Premature deaths, monthly mortality and monthly physician contacts: United States. MMWR Morb Mortal Wkly Rep. 1997;46:556.
5. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med. 1997;157:1709-1718.
6. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
7. Lave JR, Lin CC, Fine MJ. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med. 1999;20:189-198.
8. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 1995;273:214-219.
9. Summary, Evidence Report/Technology Assessment No. 9: Diagnosis and Treatment of Acute Bacterial Rhinosinusitis. Rockville, Md. US Dept of Health and Human Services, Agency for Health Care Policy and Research. 1999: AHCPR publication 99-E015.
10. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R, Niederman MS. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther. 1999;21:576-591.
11. Pechere JC, Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 2000;45:19-24.
12. Destache CJ, Dewan N, O'Donohue WJ, Campbell JC, Angelillo VA. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;43(suppl A):107-113.
13. Piccirillo JF, Mager DE, Prisse ME, Brophy RH, Goggin A. Impact of first-line vs second-line antibiotics for the treatment of acute uncomplicated sinusitis. JAMA. 2001;286:1849-1856.
14. Peng CC, Aspinall SL, Good CB, Atwood CW Jr., Chang CC. Equal effectiveness of older traditional antibiotics and newer broadspectrum antibiotics in treating patients with acute exacerbations of chronic bronchitis. South Med J. 2003;96:986-991.
15. Ball P. New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost? Int J Antimicrob Agents. 2000;16:263-272.
16. Blasi F, Tarsia P, Cosentini R, Cazzola M, Allegra L. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Expert Opin Investig Drugs. 2003;12:1165-1177.
17. Coughlin CM, Nelson M, Merchant S, Gondek K. Costs of broad-spectrum antibiotic use for acute sinusitis, chronic bronchitis, and pneumonia in a managed care population. Manag Care Interface. 2003;16:34-40, 55.
18. Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface. 2001;14:52-59.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
20. Deyo RA, Gherkin DC, Ciol MA, Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
21. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-864.
22. Kotsiou G. Choosing the right antibiotic. Aust Fam Physician. 1998;27:879-882.
23. Ben-David D, Rubinstein E. Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers. Curr Opin Infect Dis. 2002;15:151-156.
24. Amsden GW, Baird IM, Simon S, Treadway G. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest. 2003;123:772-777.
25. Weis M, Hendrick K, Tillotson G, Gravelle K. Multicenter comparative trial of ciprofloxacin versus cefuroxime axetil in the treatment of acute rhinosinusitis in a primary care setting. Rhinosinusitis Investigation Group. Clin Ther. 1998:20:921-932.
26. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med. 2000;94:337-344.
27. Hoeffken G, Meyer HP, Winter J, Verhoef L. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med. 2001;95:553-564.
28. DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med. 2000;94:1029-1037.
29. Burke T, Villanueva C, Mariano H Jr., et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther. 1999;21:1664-1677.
30. Rakkar S, Roberts K, Towe BF, et al. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int J Clin Pract. 2001;55:309-315.
31. Fogarty C, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community acquired pneumonia. Infect Med 1999;16:748-763.
32. Hirschmann JV. Antibiotics for common respiratory tract infections in adults. Arch Intern Med. 2002;162:256-264.
33. Snow V, Mottur-Pilson C, Hickner JM. Principles of appropriate antibiotic use for acute sinusitis in adults. Ann Intern Med. 2001;134:495-497.
34. Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med. 2001;134:498-505.